Web Date: April 5, 2006
GSK And Sirna In Respiratory Pact
GSK will make an initial payment of $12 million comprising cash and investment in Sirna stock. Sirna says it could rake in another $700 million in milestone payments and royalties on potential product sales.
Sirna will supply optimized and formulated short interfering RNAs against targets . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society